Novartis pulls Pluvicto prostate cancer label expansion filing in the EU

April 24, 2026 10:49 AM EDTUpdated 11 hours ago PharmaFDA+ No­var­tis pulls Plu­vic­to prostate can­cer la­bel ex­pan­sion fil­ing in the EU Anna Brown News Reporter No­var­tis has with­drawn its EU ap­pli­ca­tion for Plu­vic­to’s ex­pan­sion in­to ear­li­er prostate can­cer treat­ment, de­spite US and UK ap­proval for the same in­di­ca­tion. The Swiss … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER